Elizabeth A Platz

List of Publications by Year
in descending order

245 papers	20,231 citations	6254 80 h-index	11939 134 g-index
256 all docs	256 docs citations	256 times ranked	19013 citing authors

#	Article	IF	Citations
1	Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. International Journal of Epidemiology, 2023, 52, 71-86.	1.9	16
2	Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood. Epigenetics, 2022, 17, 460-472.	2.7	12
3	Association of Prudent, Western, and Alternate Healthy Eating Index (AHEI-2010) dietary patterns with serum testosterone and sex hormone binding globulin levels in men. Hormones, 2022, 21, 113-125.	1.9	1
4	Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer. Cancer Causes and Control, 2022, 33, 429-440.	1.8	3
5	The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study. PLoS Medicine, 2022, 19, e1003859.	8.4	20
6	Health inequity drives disease biology to create disparities in prostate cancer outcomes. Journal of Clinical Investigation, 2022, 132, .	8.2	17
7	Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1077-1089.	2.5	6
8	OUP accepted manuscript. Journal of the National Cancer Institute, 2022, , .	6.3	0
9	The prostate tissueâ€based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. Journal of Pathology: Clinical Research, 2022, 8, 481-491.	3.0	6
10	Circulating adipokine concentrations and risk of five obesityâ€related cancers: A Mendelian randomization study. International Journal of Cancer, 2021, 148, 1625-1636.	5.1	29
11	Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. Journal of the National Cancer Institute, 2021, 113, 727-734.	6.3	36
12	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6.	1.3	36
13	The association of sex steroid hormone concentrations with nonâ€alcoholic fatty liver disease and liver enzymes in US men. Liver International, 2021, 41, 300-310.	3.9	30
14	Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Nutrition and Cancer, 2021, , 1-8.	2.0	2
15	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. American Journal of Clinical Nutrition, 2021, 113, 1490-1502.	4.7	27
16	Why Do Epidemiologic Studies Find an Inverse Association Between Intraprostatic Inflammation and Prostate Cancer: A Possible Role for Colliding Bias?. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 255-259.	2.5	4
17	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	12.1	44
18	Two-Sample Mendelian Randomization Analysis of Associations Between Periodontal Disease and Risk of Cancer. JNCI Cancer Spectrum, 2021, 5, pkab037.	2.9	7

#	Article	IF	Citations
19	Association between pre-diagnostic circulating adipokines and colorectal cancer and adenoma in the CLUE II cohort. Cancer Causes and Control, 2021, 32, 871-881.	1.8	1
20	The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer. Cancer Causes and Control, 2021, 32, 965-976.	1.8	6
21	GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. PLoS ONE, 2021, 16, e0241934.	2.5	14
22	Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study. JNCI Cancer Spectrum, 2021, 5, pkab080.	2.9	6
23	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 564-575.	2.5	10
24	Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. Nutrients, 2021, 13, 4164.	4.1	3
25	Methylation-derived inflammatory measures and lung cancer risk and survival. Clinical Epigenetics, 2021, 13, 222.	4.1	8
26	Cumulative Burden of Colorectal Cancerâ€"Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	1.3	110
27	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology, 2020, 158, 1300-1312.e20.	1.3	90
28	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1086-1093.	7.0	35
29	Differences in the prevalence of modifiable risk and protective factors for prostate cancer by race and ethnicity in the National Health and Nutrition Examination Survey. Cancer Causes and Control, 2020, 31, 851-860.	1.8	2
30	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444.	6.2	124
31	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Medicine, 2020, 18, 396.	5.5	76
32	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. Human Genetics and Genomics Advances, 2020, 1, 100010.	1.7	3
33	The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial. Prostate, 2020, 80, 895-905.	2.3	0
34	Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2020, 13, 853-862.	1.5	8
35	A Prospective Study of Physical Activity, Sedentary Behavior, and Incidence and Progression of Lower Urinary Tract Symptoms. Journal of General Internal Medicine, 2020, 35, 2281-2288.	2.6	12
36	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597.	12.8	193

#	Article	IF	Citations
37	Serum Urate, Genetic Variation, and Prostate Cancer Risk: Atherosclerosis Risk in Communities (ARIC) Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1259-1261.	2.5	5
38	Nationally Representative Estimates of Serum Testosterone Concentration in Never-Smoking, Lean Men Without Aging-Associated Comorbidities. Journal of the Endocrine Society, 2019, 3, 1759-1770.	0.2	8
39	Age-Specific Serum Total and Free Estradiol Concentrations in Healthy Men in US Nationally Representative Samples. Journal of the Endocrine Society, 2019, 3, 1825-1836.	0.2	7
40	A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 2047-2054.	2.5	11
41	A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. Cancer Research, 2019, 79, 274-285.	0.9	25
42	When Is Enough, Enough? When Are More Observational Epidemiologic Studies Needed to Resolve a Research Question: Illustrations Using Biomarkerâ€"Cancer Associations. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 239-247.	2.5	3
43	Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. Clinical Chemistry, 2019, 65, 189-198.	3.2	6
44	Hyperglycemia, Classified with Multiple Biomarkers Simultaneously in Men without Diabetes, and Risk of Fatal Prostate Cancer. Cancer Prevention Research, 2019, 12, 103-112.	1.5	16
45	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	21.4	377
46	Selenium and Sex Steroid Hormones in a U.S. Nationally Representative Sample of Men: A Role for the Link between Selenium and Estradiol in Prostate Carcinogenesis?. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 578-583.	2.5	3
47	Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis, 2018, 39, 125-133.	2.8	14
48	Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate, 2018, 78, 233-238.	2.3	5
49	Consumption of caffeinated beverages and serum concentrations of sex steroid hormones in US men. Cancer Causes and Control, 2018, 29, 157-166.	1.8	2
50	Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study. Cancer Prevention Research, 2018, 11, 779-788.	1.5	19
51	Polymorphisms in genes related to inflammation and obesity and colorectal adenoma risk. Molecular Carcinogenesis, 2018, 57, 1278-1288.	2.7	13
52	Association of Statin Use With Overall and Cancer Survival. JAMA Oncology, 2018, 4, 1016.	7.1	1
53	Sustained influence of infections on prostateâ€specific antigen concentration: An analysis of changes over 10 years of followâ€up. Prostate, 2018, 78, 1024-1034.	2.3	4
54	A Pooled Analysis of 15 Prospective Cohort Studies on the Association between Fruit, Vegetable, and Mature Bean Consumption and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1276-1287.	2.5	27

#	Article	IF	Citations
55	Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate, 2017, 77, 908-919.	2.3	21
56	A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1549-1557.	2.5	61
57	A genetic variant nearGATA3implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate, 2017, 77, 1213-1220.	2.3	19
58	Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence. Prostate, 2017, 77, 412-424.	2.3	43
59	Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men. PLoS ONE, 2017, 12, e0187741.	2.5	34
60	Racial/Ethnic Differences in the Associations of Overall and Central Body Fatness with Circulating Hormones and Metabolic Factors in US Men. International Journal of Endocrinology and Metabolism, 2017, In press, e44926.	1.0	5
61	Cigarette Smoking and Prostate Cancer Mortality in Four US States, 1999â€"2010. Preventing Chronic Disease, 2016, 13, E51.	3.4	14
62	Influence of In Utero Maternal and Neonate Factors on Cord Blood Leukocyte Telomere Length: Clues to the Racial Disparity in Prostate Cancer?. Prostate Cancer, 2016, 2016, 1-8.	0.6	11
63	Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies. Journal of the National Cancer Institute, 2016, 108, djw153.	6.3	37
64	Association between serum 25â€hydroxyvitamin D and serum sex steroid hormones among men in <scp>NHANES</scp>. Clinical Endocrinology, 2016, 85, 258-266.	2.4	42
65	Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate, 2016, 76, 565-574.	2.3	5
66	Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial. Prostate, 2016, 76, 1399-1408.	2.3	6
67	Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies. International Journal of Cancer, 2016, 138, 2368-2382.	5.1	59
68	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research, 2016, 76, 2288-2300.	0.9	117
69	Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Prostate, 2015, 75, 1160-1166.	2.3	29
70	Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Prostate, 2015, 75, 1403-1418.	2.3	25
71	No Association of ApoE Genotype with Risk of Prostate Cancer: A Nested Caseâ€"Control Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1632-1634.	2.5	9
72	Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prevention Research, 2015, 8, 737-742.	1.5	11

#	Article	IF	Citations
73	Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. International Journal of Cancer, 2015, 137, 949-958.	5.1	17
74	Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes and Control, 2015, 26, 35-44.	1.8	8
75	Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2015, 8, 590-596.	1.5	11
76	Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies. Cancer Causes and Control, 2015, 26, 1449-1460.	1.8	56
77	Postdiagnostic Statin Use and the Risk of Lethal Prostate Cancer in the Health Professionals Follow-up Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1638-1640.	2.5	12
78	Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. American Journal of Clinical Nutrition, 2015, 102, 1142-1157.	4.7	107
79	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology, 2015, 28, 128-137.	5.5	136
80	Prediagnostic plasma <scp>IGFBP</scp>â€1, <scp>IGF</scp>â€1 and risk of prostate cancer. International Journal of Cancer, 2015, 136, 2418-2426.	5.1	76
81	Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 847-856.	2.5	195
82	A Peripheral Circulating TH1 Cytokine Profile Is Inversely Associated with Prostate Cancer Risk in CLUE II. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2561-2567.	2.5	18
83	The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. Cancer Causes and Control, 2014, 25, 409-418.	1.8	10
84	Association between endogenous sex steroid hormones and insulin-like growth factor proteins in US men. Cancer Causes and Control, 2014, 25, 353-363.	1.8	4
85	Statin Drug Use is Not Associated with Prostate Cancer Risk in Men Who are Regularly Screened. Journal of Urology, 2014, 192, 379-384.	0.4	43
86	A Prospective Study of Obesity, and the Incidence and Progression of Lower Urinary Tract Symptoms. Journal of Urology, 2014, 191, 715-721.	0.4	67
87	To Adjust or Not in Studies on Racial Differences in Hormone Concentrations? Depends on the Question!. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 407-408.	3.6	0
88	Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate, 2014, 74, 1655-1662.	2.3	52
89	Telomere length as a risk factor for hereditary prostate cancer. Prostate, 2014, 74, 359-364.	2.3	27
90	Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes and Control, 2014, 25, 625-632.	1.8	27

#	Article	IF	Citations
91	GSTP1Promoter Methylation is Associated with Recurrence in Early Stage Prostate Cancer. Journal of Urology, 2014, 192, 1542-1548.	0.4	48
92	Associations between urinary soy isoflavonoids and two inflammatory markers in adults in the United States in 2005â€“2008. Cancer Causes and Control, 2013, 24, 1185-1196.	1.8	15
93	Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes and Control, 2013, 24, 2077-2087.	1.8	50
94	Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer. Cancer Causes and Control, 2013, 24, 175-180.	1.8	10
95	Racial/ethnic differences in serum sex steroid hormone concentrations in US adolescent males. Cancer Causes and Control, 2013, 24, 817-826.	1.8	23
96	Androgenetic alopecia at various ages and prostate cancer risk in an equal-access multiethnic caseâ€“control series of veterans. Cancer Causes and Control, 2013, 24, 1045-1052.	1.8	13
97	Insulin-Like Growth Factors and Insulin-Like Growth Factorâ€“Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2013, 6, 91-99.	1.5	28
98	Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death. Cancer Discovery, 2013, 3, 1130-1141.	9.4	77
99	A Prospective Study of Statin Drug Use and Lower Urinary Tract Symptoms in Older Men. American Journal of Epidemiology, 2013, 178, 797-803.	3.4	15
100	Association of serum calcium with serum sex steroid hormones in men in NHANES III. Aging Male, 2013, 16, 151-158.	1.9	4
101	Colorectal Cancer in Women. , 2013, , 1209-1219.		0
102	Opportunities for the Primary Prevention of Colorectal Cancer in the United States. Cancer Prevention Research, 2012, 5, 138-145.	1.5	24
103	Variation in IL10 and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer Recurrence. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1774-1782.	2.5	49
104	Vitamin Dâ€“Related Genetic Variation, Plasma Vitamin D, and Risk of Lethal Prostate Cancer: A Prospective Nested Caseâ€“Control Study. Journal of the National Cancer Institute, 2012, 104, 690-699.	6.3	196
105	Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Causes and Control, 2012, 23, 1511-1518.	1.8	15
106	Overview. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 727-728.	1.6	0
107	Association Between Sex Steroid Hormones and Hematocrit in a Nationally Representative Sample of Men. Journal of Andrology, 2012, 33, 1332-1341.	2.0	25
108	Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Modern Pathology, 2012, 25, 1543-1549.	5.5	124

#	Article	IF	Citations
109	Incidence and Progression of Lower Urinary Tract Symptoms in a Large Prospective Cohort of United States Men. Journal of Urology, 2012, 188, 496-501.	0.4	77
110	The Role of Obesity in Cancer Survival and Recurrence. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1244-1259.	2.5	248
111	Serum sex steroid hormones and frailty in older American men of the Third National Health and Nutrition Examination Survey (NHANES III). Aging Male, 2012, 15, 208-215.	1.9	53
112	Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990â€“2006. International Journal of Cancer, 2012, 131, 1667-1677.	5.1	55
113	Association between plasma 25â€OH vitamin D and testosterone levels in men. Clinical Endocrinology, 2012, 77, 106-112.	2.4	133
114	Epidemiology, Etiology, and Prevention of Prostate Cancer. , 2012, , 2704-2725.e7.		12
115	Association of Statin Use With Pathological Tumor Characteristics and Prostate Cancer Recurrence After Surgery. Journal of Urology, 2011, 185, 1268-1273.	0.4	46
116	Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas. American Journal of Surgical Pathology, 2011, 35, 1014-1020.	3.7	135
117	The prevalence of low sex steroid hormone concentrations in men in the Third National Health and Nutrition Examination Survey (NHANES III). Clinical Endocrinology, 2011, 75, 232-239.	2.4	47
118	Association of serum Î±-tocopherol with sex steroid hormones and interactions with smoking: implications for prostate cancer risk. Cancer Causes and Control, 2011, 22, 827-836.	1.8	13
119	Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes and Control, 2011, 22, 1141-1151.	1.8	92
120	Plasma insulinâ€like growth factor 1 is positively associated with lowâ€grade prostate cancer in the Health Professionals Followâ€up Study 1993â€“2004. International Journal of Cancer, 2011, 128, 660-667.	5.1	31
121	Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: A simulation study. Cancer Epidemiology, 2011, 35, e6-e11.	1.9	11
122	Racial Variation in Umbilical Cord Blood Leptin Concentration in Male Babies. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 665-671.	2.5	6
123	Weight Gain Is Associated with an Increased Risk of Prostate Cancer Recurrence after Prostatectomy in the PSA Era. Cancer Prevention Research, 2011, 4, 544-551.	1.5	75
124	A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment. Cancer Discovery, 2011, 1, 68-77.	9.4	145
125	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2â€“ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	5.5	57
126	Serum Lycopene Concentration and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 638-646.	2.5	75

#	Article	IF	Citations
127	Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes and Control, 2010, 21, 61-68.	1.8	91
128	Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001â€"2004. Cancer Causes and Control, 2010, 21, 671-678.	1.8	39
129	Intra-individual variation in serum C-reactive protein over 4Âyears: an implication for epidemiologic studies. Cancer Causes and Control, 2010, 21, 847-851.	1.8	31
130	Association of serum cholesterol and cholesterol-lowering drug use with serum sex steroid hormones in men in NHANES III. Cancer Causes and Control, 2010, 21, 1575-1583.	1.8	20
131	Statin medication use and the risk of biochemical recurrence after radical prostatectomy. Cancer, 2010, 116, 3389-3398.	4.1	112
132	Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. International Journal of Cancer, 2010, 127, 1650-1659.	5.1	88
133	Sex Steroid Hormone Concentrations and Risk of Death in US Men. American Journal of Epidemiology, 2010, 171, 583-592.	3.4	124
134	Association between C-Peptide Concentration and Prostate Cancer Incidence in the CLUE II Cohort Study. Cancer Prevention Research, 2010, 3, 1334-1341.	1.5	18
135	Coumaphos Exposure and Incident Cancer among Male Participants in the Agricultural Health Study (AHS). Environmental Health Perspectives, 2010, 118, 92-96.	6.0	31
136	Diet, Supplement Use, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. American Journal of Epidemiology, 2010, 172, 566-577.	3.4	139
137	Inflammation as a Target in Prostate Cancer. , 2010, , 375-386.		3
138	Prospective Study of JC Virus Seroreactivity and the Development of Colorectal Cancers and Adenomas. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1515-1523.	2.5	22
139	Does statin use affect the risk of developing prostate cancer?. Nature Reviews Urology, 2009, 6, 70-71.	1.4	6
140	Racial Variation in Sex Steroid Hormones and the Insulin-Like Growth Factor Axis in Umbilical Cord Blood of Male Neonates. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1484-1491.	2.5	40
141	A Simulation Study of Control Sampling Methods for Nested Case-Control Studies of Genetic and Molecular Biomarkers and Prostate Cancer Progression. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 706-711.	2.5	38
142	A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. American Journal of Clinical Nutrition, 2009, 90, 1623-1631.	4.7	120
143	Association of cigarette smoking, alcohol consumption, and physical activity with sex steroid hormone levels in US men. Cancer Causes and Control, 2009, 20, 877-886.	1.8	142
144	Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes and Control, 2009, 20, 1739-1751.	1.8	132

#	Article	IF	Citations
145	Association of IL10 and Other immune responseâ€•and obesityâ€•related genes with prostate cancer in CLUE II. Prostate, 2009, 69, 874-885.	2.3	117
146	Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. Clinical Endocrinology, 2009, 70, 26-34.	2.4	51
147	Endogenous sex steroid hormones and measures of chronic kidney disease (CKD) in a nationally representative sample of men. Clinical Endocrinology, 2009, 71, 246-252.	2.4	32
148	TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Modern Pathology, 2009, 22, 359-365.	5.5	51
149	TMPRSS2â€"ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Modern Pathology, 2009, 22, 1415-1422.	5.5	48
150	Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Current Opinion in Pharmacology, 2009, 9, 419-426.	3.5	64
151	Prospective Study of Trichomonas vaginalis Infection and Prostate Cancer Incidence and Mortality: Physicians' Health Study. Journal of the National Cancer Institute, 2009, 101, 1406-1411.	6.3	162
152	Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2807-2813.	2.5	150
153	Risk Factors for Hearing Loss in US Adults. Otology and Neurotology, 2009, 30, 139-145.	1.3	216
154	C-reactive protein and colorectal adenoma in the CLUE II cohort. Cancer Causes and Control, 2008, 19, 559-567.	1.8	30
155	Inflammation and prostate cancer: A focus on infections. Current Urology Reports, 2008, 9, 243-249.	2.2	48
156	TNF polymorphisms and prostate cancer risk. Prostate, 2008, 68, 400-407.	2.3	42
157	Câ€•reactive protein and colorectal cancer risk: A systematic review of prospective studies. International Journal of Cancer, 2008, 123, 1133-1140.	5.1	168
158	Association between plasma cholesterol and prostate cancer in the PSA era. International Journal of Cancer, 2008, 123, 1693-1698.	5.1	117
159	Prevalence of Hearing Loss and Differences by Demographic Characteristics Among US Adults<subtitle>Data From the National Health and Nutrition Examination Survey, 1999-2004</subtitle>. Archives of Internal Medicine, 2008, 168, 1522.	3.8	762
160	Low Testosterone and Risk of Premature Death in Older Men: Analytical and Preanalytical Issues in Measuring Circulating Testosterone. Clinical Chemistry, 2008, 54, 1110-1112.	3.2	24
161	The Influence of Statin Medications on Prostate-specific Antigen Levels. Journal of the National Cancer Institute, 2008, 100, 1511-1518.	6.3	145
162	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. Annals of Internal Medicine, 2008, 149, 461.	3.9	263

#	Article	IF	Citations
163	Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis, 2007, 29, 568-572.	2.8	29
164	Serum Estrogen, But Not Testosterone, Levels Differ between Black and White Men in a Nationally Representative Sample of Americans. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2519-2525.	3.6	150
165	Androgens and Diabetes in Men. Diabetes Care, 2007, 30, 234-238.	8.6	309
166	Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data. Epidemiologic Reviews, 2007, 29, 88-97.	3.5	199
167	Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2175-2180.	2.5	19
168	Serum Sex Steroid Hormones and Lower Urinary Tract Symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology, 2007, 69, 708-713.	1.0	81
169	Inflammation in the etiology of prostate cancer: An epidemiologic perspective. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 242-249.	1.6	53
170	Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. American Journal of Clinical Nutrition, 2007, 85, 523-529.	4.7	83
171	Risk factors for prostate cancer incidence and progression in the health professionals followâ€up study. International Journal of Cancer, 2007, 121, 1571-1578.	5.1	441
172	Acne and risk of prostate cancer. International Journal of Cancer, 2007, 121, 2688-2692.	5.1	78
173	RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate, 2007, 67, 849-854.	2.3	24
174	Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate, 2007, 67, 911-923.	2.3	93
175	Polymorphic variants in Î±â€methylacylâ€CoA racemase and prostate cancer. Prostate, 2007, 67, 1487-1497.	2.3	20
176	Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination survey. Prostate, 2007, 67, 1693-1698.	2.3	20
177	Inflammation in prostate carcinogenesis. Nature Reviews Cancer, 2007, 7, 256-269.	28.4	1,352
178	Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. Cancer Causes and Control, 2007, 18, 41-50.	1.8	110
179	Statin Drugs and Risk of Advanced Prostate Cancer. Journal of the National Cancer Institute, 2006, 98, 1819-1825.	6.3	365
180	A Novel Role of Myosin VI in Human Prostate Cancer. American Journal of Pathology, 2006, 169, 1843-1854.	3.8	133

#	Article	IF	Citations
181	Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 939-945.	2.5	161
182	Sexually Transmitted Infections and Prostatic Inflammation/Cell Damage as Measured by Serum Prostate Specific Antigen Concentration. Journal of Urology, 2006, 175, 1937-1942.	0.4	60
183	Obesity, Serum Prostate Specific Antigen and Prostate Size: Implications for Prostate Cancer Detection. Journal of Urology, 2006, 175, 500-504.	0.4	156
184	What Can Geography Tell Us About Prostate Cancer?. American Journal of Preventive Medicine, 2006, 30, S7-S15.	3.0	40
185	C-reactive protein levels and subsequent cancer outcomes: Results from a prospective cohort study. European Journal of Cancer, 2006, 42, 704-707.	2.8	57
186	Concordance Rates and Modifiable Risk Factors for Lower Urinary Tract Symptoms in Twins. Epidemiology, 2006, 17, 419-427.	2.7	36
187	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	3.7	123
188	Are Findings from Studies of Obesity and Prostate Cancer Really in Conflict?. Cancer Causes and Control, 2006, 17, 5-9.	1.8	93
189	C47T polymorphism in manganese superoxide dismutase (MnSOD), antioxidant intake and survival. Mechanisms of Ageing and Development, 2006, 127, 371-377.	4.6	11
190	Gonorrhea, Syphilis, Clinical Prostatitis, and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2160-2166.	2.5	82
191	The Metabolic Syndrome Is Associated with Reduced Risk of Prostate Cancer. American Journal of Epidemiology, 2006, 164, 1094-1102.	3.4	141
192	Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1977-1983.	2.5	300
193	Obesity, Adipokines, and Prostate Cancer in a Prospective Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1331-1335.	2.5	121
194	Genetic Polymorphisms of Interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and Risk of Prostate Cancer. Cancer Research, 2006, 66, 4525-4530.	0.9	124
195	Metabolic Factors Associated with Benign Prostatic Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2562-2568.	3.6	281
196	Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health And Nutrition Examination Survey. BJU International, 2005, 96, 77-82.	2.5	110
197	Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes and Control, 2005, 16, 255-262.	1.8	65
198	Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate, 2005, 62, 27-33.	2.3	99

#	Article	IF	Citations
199	Stronger Association between Obesity and Biochemical Progression after Radical Prostatectomy among Men Treated in the Last 10 Years. Clinical Cancer Research, 2005, 11, 2883-2888.	7.0	60
200	Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 2005, 26, 1170-1181.	2.8	330
201	Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 390-396.	2.5	81
202	Sexually Transmitted Infections, Prostatitis, Ejaculation Frequency, and the Odds of Lower Urinary Tract Symptoms. American Journal of Epidemiology, 2005, 162, 898-906.	3.4	39
203	ASSOCIATION BETWEEN SERUM ADIPONECTIN, AND PATHOLOGICAL STAGE AND GRADE IN MEN UNDERGOING RADICAL PROSTATECTOMY. Journal of Urology, 2005, 174, 1266-1270.	0.4	64
204	Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology, 2005, 66, 108-113.	1.0	77
205	Lifestyle and benign prostatic hyperplasia in older men: what do we know?. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2005, 2, 230-235.	0.2	12
206	Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1262-1269.	2.5	212
207	Epidemiology of Cancer Risk: Vitamin D and Calcium. , 2005, , 1617-1634.		3
208	C-Reactive Protein and the Risk of Incident Colorectal Cancer. JAMA - Journal of the American Medical Association, 2004, 291, 585.	7.4	457
209	Associations of Obesity with Lower Urinary Tract Symptoms and Noncancer Prostate Surgery in the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology, 2004, 159, 390-397.	3.4	118
210	Fruit, Vegetable, and Antioxidant Intake and All-Cause, Cancer, and Cardiovascular Disease Mortality in a Community-dwelling Population in Washington County, Maryland. American Journal of Epidemiology, 2004, 160, 1223-1233.	3.4	313
211	Ejaculation Frequency and Subsequent Risk of Prostate Cancer. JAMA - Journal of the American Medical Association, 2004, 291, 1578.	7.4	108
212	Plasma and Dietary Carotenoids, and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 260-269.	2.5	178
213	Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer. Cancer Causes and Control, 2004, 15, 255-265.	1.8	212
214	No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate, 2004, 59, 393-400.	2.3	41
215	Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays. Prostate, 2004, 61, 215-227.	2.3	85
216	Prostate cancer association studies: Pitfalls and solutions to cancer misclassification in the PSA era. Journal of Cellular Biochemistry, 2004, 91, 553-571.	2.6	50

#	Article	IF	Citations
217	Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. Journal of Cellular Biochemistry, 2004, 91, 459-477.	2.6	164
218	Epidemiology of Inflammation and Prostate Cancer. Journal of Urology, 2004, 171, S36-40.	0.4	205
219	Association of prostate cancer risk with insulin, glucose, and anthropometry in the baltimore longitudinal study of aging. Urology, 2004, 63, 253-258.	1.0	84
220	Association between serum concentrations of micronutrients and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey. Urology, 2004, 64, 504-509.	1.0	26
221	The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 237-253.	2.5	151
222	1543: The Prevalence and Extent of Autopsy Benign Prostatic Hyperplasia (BPH) is Less in South East Asian Men than North American Men. Journal of Urology, 2004, 171, 406-407.	0.4	4
223	Family history of prostate cancer and obesity in relation to highâ€grade disease and extraprostatic extension in young men with prostate cancer. Prostate, 2003, 55, 140-146.	2.3	85
224	Human prostate cancer precursors and pathobiology. Urology, 2003, 62, 55-62.	1.0	229
225	Hypermethylation of the Human Glutathione S-Transferase-Ï€ Gene (GSTP1) CpG Island Is Present in a Subset of Proliferative Inflammatory Atrophy Lesions but Not in Normal or Hyperplastic Epithelium of the Prostate. American Journal of Pathology, 2003, 163, 923-933.	3.8	290
226	Association of energy intake with prostate cancer in a long-term aging study: Baltimore longitudinal study of aging (United States). Urology, 2003, 61, 297-301.	1.0	39
227	Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 84-9.	2.5	112
228	Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 412-8.	2.5	76
229	Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Research, 2003, 63, 8542-8.	0.9	56
230	Telomere Length Assessment in Human Archival Tissues. American Journal of Pathology, 2002, 160, 1259-1268.	3.8	207
231	Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology, 2002, 59, 877-883.	1.0	140
232	Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology, 2002, 60, 1118-1123.	1.0	59
233	Energy Imbalance and Prostate Cancer. Journal of Nutrition, 2002, 132, 3471S-3481S.	2.9	55
234	Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. American Journal of Clinical Nutrition, 2002, 75, 689-697.	4.7	99

#	Article	IF	Citations
235	Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Research, 2002, 62, 2220-6.	0.9	384
236	Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Research, 2002, 62, 6405-9.	0.9	202
237	Diet: Selenium, Zinc, and Prostate Cancer. Epidemiologic Reviews, 2001, 23, 93-101.	3.5	94
238	Amplified in Breast Cancerâ€1 Glutamine Repeat and Prostate Cancerâ€ƒRisk. Prostate Journal, 2000, 2, 27-32.	0.2	14
239	Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes and Control, 2000, 11, 579-588.	1.8	234
240	RACE, ETHNICITY AND BENIGN PROSTATIC HYPERPLASIA IN THE HEALTH PROFESSIONALS FOLLOW-UP STUDY. Journal of Urology, 2000, 163, 490-495.	0.4	67
241	RACE, ETHNICITY AND BENIGN PROSTATIC HYPERPLASIA IN THE HEALTH PROFESSIONALS FOLLOW-UP STUDY. Journal of Urology, 2000, , 490.	0.4	3
242	Alcohol Consumption, Cigarette Smoking, and Risk of Benign Prostatic Hyperplasia. American Journal of Epidemiology, 1999, 149, 106-115.	3.4	127
243	The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology, 1999, 53, 121-125.	1.0	114
244	Retrospective Analysis of Birth Weight and Prostate Cancer in the Health Professionals Follow-up Study. American Journal of Epidemiology, 1998, 147, 1140-1144.	3.4	43
245	Physical Activity and Benign Prostatic Hyperplasia. Archives of Internal Medicine, 1998, 158, 2349.	3.8	132